Crinetics Acquisition Creates A ‘Fifth Commercial Pillar’ For Vertex, Says Analyst – Why HC Wainwright Sees A 24% Upside Potential In VRTX Stock
H.C. Wainwright said Crinetics’ lead product Palsonify adds a meaningful commercial product and establishes endocrinology as Vertex’s fifth major business pillar. The brokerage maintained a ‘Buy’ rating on Vertex with a $641 price target. Vertex said the acquisition could eventually contribute about $5 billion in annual revenue. Wall Street has a very favorable view of … Read more